Skip to content

NxStage Medical, Inc.

Delisted

CIK 1333170fmd_1WJ93VJ4P5DKY3VYRNX8S0D6T3Manufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2018, 36 periods

Latest annual · FY2014

Millions
Total revenues
302
Gross profit
168
Operating income
(14)
Net income
(14)
Free cash flow
(4)

Latest quarter · Q3 FY2018

Millions
Total revenues
108
Gross profit
47
Operating income
1
Net income
1
Free cash flow
6
Open Financials

Key stats

Open Analysis

Compound annual growth

Net income, 5 yearsFY2012 to FY2017
n/m

NxStage Medical, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2017FY2016ChangeSource
Gross profit$168.3 million$152 million+10.7%10-K 2018-02-16 · proof
Operating income-$13.9 million-$4.3 million10-K 2018-02-16 · proof
Net income-$14 million-$4.8 million10-K 2018-02-16 · proof
Cash from operating activities$4.8 million$4.6 million+4.7%10-K 2018-02-16 · proof
Free cash flow-$4.4 million-$4.3 million10-K 2018-02-16 · proof
Total assets$325.6 million$317.2 million+2.7%10-K 2018-02-16 · proof
Total liabilities$112.6 million$115.1 million-2.2%10-K 2018-02-16 · proof
Cash and cash equivalents$64.9 million$59.6 million+8.9%10-K 2018-02-16 · proof
Total debt$621,000$1.6 million-62%10-K 2018-02-16 · proof
What was NxStage Medical, Inc.'s gross profit in fiscal 2017?
NxStage Medical, Inc. reported gross profit of $168.3 million for fiscal 2017 (the year ended Dec 31, 2017), against $152 million the year before (+10.7%). Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What was NxStage Medical, Inc.'s operating income in fiscal 2017?
NxStage Medical, Inc. reported operating income of -$13.9 million for fiscal 2017 (the year ended Dec 31, 2017), against -$4.3 million the year before. Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What was NxStage Medical, Inc.'s net income in fiscal 2017?
NxStage Medical, Inc. reported net income of -$14 million for fiscal 2017 (the year ended Dec 31, 2017), against -$4.8 million the year before. Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What was NxStage Medical, Inc.'s cash from operating activities in fiscal 2017?
NxStage Medical, Inc. reported cash from operating activities of $4.8 million for fiscal 2017 (the year ended Dec 31, 2017), against $4.6 million the year before (+4.7%). Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What was NxStage Medical, Inc.'s free cash flow in fiscal 2017?
NxStage Medical, Inc. reported free cash flow of -$4.4 million for fiscal 2017 (the year ended Dec 31, 2017), against -$4.3 million the year before. Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What are NxStage Medical, Inc.'s total assets?
As of Dec 31, 2017, NxStage Medical, Inc. reported total assets of $325.6 million, against $317.2 million a year earlier (+2.7%). Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What are NxStage Medical, Inc.'s total liabilities?
As of Dec 31, 2017, NxStage Medical, Inc. reported total liabilities of $112.6 million, against $115.1 million a year earlier (-2.2%). Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What are NxStage Medical, Inc.'s cash and cash equivalents?
As of Dec 31, 2017, NxStage Medical, Inc. reported cash and cash equivalents of $64.9 million, against $59.6 million a year earlier (+8.9%). Source: the 10-K filed with the SEC on Feb 16, 2018. SEC
What is NxStage Medical, Inc.'s total debt?
As of Dec 31, 2017, NxStage Medical, Inc. reported total debt of $621,000, against $1.6 million a year earlier (-62%). Source: the 10-K filed with the SEC on Feb 16, 2018. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1333170&period_type=annual&limit=5"

Information only, not investment advice.